AstraZeneca has acquired global rights to advance and commercialize Dizal Pharmaceutical’s Zegfrovy, a lung cancer drug already approved in the U.S., through a licensing agreement worth up to $1.5 billion.
AstraZeneca has acquired global rights to advance and commercialize Dizal Pharmaceutical’s Zegfrovy, a lung cancer drug already approved in the U.S., through a licensing agreement worth up to $1.5 billion.
READ MORE
Spero Therapeutics and Innovent Biologics have entered a deal worth up to $1.1 billion for development rights to SP001, targeting IgG4-related disease with a novel anti-CD40L antibody.
BioSpace’s Q2 2026 Biopharma Job Market Report offers a comprehensive look at hiring trends, market shifts, and the evolving landscape of talent acquisition, with signs pointing toward sustained R&D activity and strategic recruitment.
A bipartisan bill aiming to reduce barriers to clinical trials has gathered endorsements from nearly 200 healthcare and advocacy groups, highlighting growing momentum to reform research participation for underrepresented populations.
GSK’s immunotherapy Jemperli has achieved a pivotal milestone in a Phase 2 study targeting a rare form of rectal cancer, potentially setting a new paradigm for regulatory approval and treatment pathways in oncology.
Healthcare’s cybersecurity efforts are shifting beyond the protection of electronic health records, extending deeply into the defense of medical innovation, algorithms, and intellectual property driving the next wave of medicine.
Recent conversations on obesity genetics remain overly focused on two variants, overshadowing the sophisticated genetic landscape that drives risk—and missing crucial insight for tailored interventions.
As states consider cutting caregiver wages amid broader Medicaid funding changes, many families supporting people with disabilities are facing grim financial instability—some on the brink of homelessness.
EMD Serono has announced a reduction of 70 positions within its research and development staff, joining a broader wave of job cuts rippling across the biotech sector. The decision raises questions about the state of biopharma innovation and the employment landscape.
A former research director at Mayo Clinic has filed a lawsuit alleging retaliation after raising concerns about AI safety and patient privacy, raising critical questions for the industry about oversight, transparency, and the ethical use of artificial intelligence in healthcare.
A debate is intensifying about the role of patient voices in FDA regulatory decisions, especially for rare diseases. Advocates argue for patient participation in advisory committees to ensure the agency’s decisions serve the people most affected.
